{"id":999563,"date":"2026-09-01T19:10:40","date_gmt":"2026-09-01T23:10:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-announces-participation-in-upcoming-investor-conferences\/"},"modified":"2026-09-01T19:10:40","modified_gmt":"2026-09-01T23:10:40","slug":"cellectis-announces-participation-in-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-announces-participation-in-upcoming-investor-conferences\/","title":{"rendered":"Cellectis Announces Participation in Upcoming Investor Conferences"},"content":{"rendered":"
\n

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) — Cellectis (the \u201cCompany\u201d) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will participate in the upcoming investor conferences:<\/p>\n

\n Wells Fargo 21st Annual Healthcare Conference \u2013 Boston, MA<\/strong>
\n
September 10, 2026<\/p>\n

\n Baird 2026 Global Healthcare Conference \u2013 New York<\/strong>
\n
September 15, 2026
Company presentation at 12:50 – 1:20 p.m. ET<\/p>\n

\n Fall Focus: Barclays Biotech 1×1 Day \u2013 New York<\/strong>
\n
October 6, 2026<\/p>\n

\n Stifel 2026 Healthcare Conference \u2013 New York<\/strong>
\n
November 10-12, 2026<\/p>\n

\n Jefferies Global Healthcare Conference \u2013 London<\/strong>
\n
November 16-19, 2026<\/p>\n

Cellectis’ management team will be available for meetings with investors throughout these conferences. To arrange a meeting, please contact the respective conference representatives or Cellectis Investor Relations at investors@cellectis.com<\/a><\/p>\n

Any available webcast will be posted to the Company’s website at https:\/\/www.cellectis.com\/en\/investors\/events-and-webcasts\/<\/a>.<\/p>\n

\n About\u00a0Cellectis<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0
Cellectis\u00a0is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company\u00a0utilizes\u00a0an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and\u00a0ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities,\u00a0Cellectis\u00a0is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.\u00a0Cellectis\u2019 headquarters are in Paris, France, with locations in New York and Raleigh, NC.\u00a0Cellectis\u00a0is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com<\/a> and follow Cellectis on LinkedIn<\/a> and X<\/a>.<\/p>\n

\n For further information on Cellectis, please contact:<\/strong>\n <\/p>\n

\n Media contacts:<\/strong>
\n
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33,<\/p>\n

Patricia Sosa Navarro, Chief of Staff to the CEO,\u00a0+33 (0)7 76 77 46 93, media@cellectis.com<\/a><\/p>\n

\n Investor Relations contact:<\/strong>
\n
Arthur Stril, Chief Financial Officer & Chief Business Officer,\u00a0investors@cellectis.com<\/a><\/p>\n

\n Attachment<\/strong>\n <\/p>\n